Conditions: Community-Acquired Pneumonia (CAP)
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 158
Healthy volunteers: no

Brief summary:
The purpose of this study is to determine whether RX-1741, an oxazolidinone antibiotic, is safe and effective in the treatment of mild to moderate community acquired pneumonia (CAP).

Detailed description:

Arms:
arm 1: Radezolid 300 mg arm 2: Radezolid 450 mg arm 3: Radezolid 450 mg BID

Interventions: intervention 1: Radezolid intervention 2: Radezolid intervention 3: Radezolid
Intervention descriptions: intervention 1: 300 mg/day, orally for 7-10 days intervention 2: 450 mg/day orally for 7-10 days intervention 3: 900 mg/day orally for 7-10 days

Protocol document: